Antimicrobial peptides (AMPs) are gaining attention as a potential solution to the global antibiotic resistance crisis. These naturally occurring molecules, which are part of the innate immune system, kill bacteria, fungi, and viruses through mechanisms that make resistance development less likely than with traditional antibiotics.
AMPs are short, positively charged peptides that interact with microbial membranes, disrupting their integrity and causing cell death. This membrane-targeting mechanism is fundamentally different from the mechanisms of most conventional antibiotics, which target specific intracellular processes. The broad-spectrum activity and low likelihood of resistance make AMPs attractive candidates for development.
Despite their promise, AMPs face challenges for therapeutic development. These include susceptibility to proteolytic degradation, potential toxicity to mammalian cells, and high manufacturing costs. Research is focused on addressing these challenges through peptide engineering, formulation development, and advanced synthesis technologies.
Recent advances in AI are accelerating AMP discovery. A generative artificial intelligence approach has been developed for the discovery of antimicrobial peptides against multidrug-resistant bacteria[reference:117]. Researchers at the University of Pennsylvania have developed an AI tool to design promising peptides for laboratory testing[reference:118]. These advances are expanding the pipeline of AMP candidates for clinical development.
Clinical applications of AMPs include topical treatments for skin infections, systemic therapies for drug-resistant infections, and prophylactic use in high-risk patients. Several AMPs are in clinical development, with some approved for topical use. At PeptideHub, we provide high-quality AMPs for research applications, supporting the development of next-generation antimicrobial therapies.